New Drug Approval Case Study: USFDA approval of Zeposia, delayed market launch likely due to COVID-19
U.S. Food and Drug Administration (FDA) has approved ZEPOSIA® (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple... Read More
Case study : USFDA approval of Amgen leukemia drug blinatumomab
U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more... Read More